WO2003105883A1 - Behandlung von schweren infektionen und septischem schock - Google Patents
Behandlung von schweren infektionen und septischem schock Download PDFInfo
- Publication number
- WO2003105883A1 WO2003105883A1 PCT/EP2003/005694 EP0305694W WO03105883A1 WO 2003105883 A1 WO2003105883 A1 WO 2003105883A1 EP 0305694 W EP0305694 W EP 0305694W WO 03105883 A1 WO03105883 A1 WO 03105883A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- rtd
- bacteria
- therapy
- gram
- lps
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
Definitions
- the invention relates to the use of Rhesus-Theta-Defensin 1 (RTD-1) for the manufacture of a medicament for the treatment and / or prophylaxis of patients with severe infections (bacteria) including septic shock.
- RTD-1 Rhesus-Theta-Defensin 1
- Sepsis is a severe, life-threatening clinical picture resulting from an infection with bacteria on a systemic level (bacteremia) and other clinical findings according to the internationally valid definition (Madot, I. and
- Sepsis is characterized by fever, hypotension and so-called shock symptoms (e.g. shock lung, shock kidney, gastrointestinal bleeding; generally referred to as multi-organ failure).
- shock symptoms e.g. shock lung, shock kidney, gastrointestinal bleeding; generally referred to as multi-organ failure.
- shock symptoms e.g. shock lung, shock kidney, gastrointestinal bleeding; generally referred to as multi-organ failure.
- These different symptoms are the clinical signs of pathophysiological processes caused by the germs themselves or their products, eg endotoxins, hemolysins or pyrogens.
- Pathological conditions such as severe nervous disorders can also be Burns, trauma or acute lung changes with subsequent or simultaneous colonization with bacteria, fungi or niren occur. In these cases, too, symptoms of shock are found, with only partial direct diagnosis of the bacteria or other pathogens being possible.
- the patient's own factors of the immune system are both protective and harmful, depending on concentration, place of action and the like.
- the trigger for these events is by definition the presence of bacteria and / or the presence of bacterial products such as LPS / LTA and others. This leads to the release of e.g. Tumor ⁇ ecrosis factor- ⁇ , interleukin-1 (IL-1), interleukin-6 (IL-6) and interleukin-8 (IL-8), as well as factors that influence coagulation (e.g.
- PAF platelet activating factor
- factors that intervene in a regulatory manner on the resulting inflammatory process such as prostaglandins, leukotrienes, interleukin-10.
- PAF platelet activating factor
- factors that intervene in a regulatory manner on the resulting inflammatory process such as prostaglandins, leukotrienes, interleukin-10.
- Another approach is to influence the clinical picture with immunomodulatory treatments in order to prevent or at least alleviate an excessive response of the organism to bacteria or bacterial products and thus to avoid organ failure (Zanotti, S. et al. (2002), Expert Opin. Investig. Drugs 11, 1061-1075).
- Soluble immune system mediators which are administered as therapy, are of particular interest. These mediators include the so-called defensins, molecules with anti-bacterial, anti-fungal or even anti-viral properties (Kagan, B.L. et al. (1994), Toxicology 87, 131-149;
- RTD-1 A defensin from immune cells of the rhesus monkey (Rhesus-Theta-Defensin 1; RTD-1) was isolated and its properties, its broad antibacterial activity, also against non-growing bacteria, and its antifungal activity have been described in detail (Tang et al. (1999) , Science 286, 498-502; Tran et al. (2002), J. Biol.
- RTD-1 is characterized by some characteristic and determining properties against other defensins or cationic peptides. On the one hand, RTD-1 is a small circular peptide and, in contrast to other defensins, is therefore stable against degradation and degradation. RTD-1 shows no dependence on the effect of salts in the
- RTD-1 a further effect of the RTD-1 is surprisingly found in states of bacteremia with subsequent sepsis and septic shock, as well as such disease states after exposure to bacterial products such as LPS.
- RTD-1 intervenes in the disease process by 1. showing anti-microbial activity against various pathogens, 2. neutralizing effect on bacterial products such as LPS or LTA (effect on products of gram-positive and gram-negative bacteria) , which also allows prophylactic therapy, 3. has an immunomodulatory effect in the sense of mediator modulation, and 4. has a regulated anticoagulant effect.
- the combined effect on various disease-relevant parameters results in a clearly improved therapeutic success with simplified therapy.
- therapy with RTD-1 closes the current standard therapies (e.g. antibiotics, circulatory stabilizers
- RTD-1 Treatment with RTD-1 leads to increased survival of mice with severe bacteremia after application of living bacteria, both after infection with gram-positive and gram-negative bacteria. Surprisingly, there is no dependency on the minimum inhibitory concentration of RTD-1 on the bacterium used.
- mice with symptoms of septic shock after administration of LPS or SEB also shows a significantly increased survival under therapy with
- RTD first Cytokine analyzes in the serum or plasma of the animals show a regulation of the release of soluble mediators.
- a decrease in pro-inflammatory cytokines such as TNF-, IL-6, MIF
- regulatory factors such as IFN- ⁇ , IL-10
- Comparable results are found in whole human blood, and the values for pro-inflammatory cytokines and chemokines are lowered.
- RTD-1 Under the influence of RTD-1, there is a dose-dependent increase in the clotting time of human plasma and human whole blood. RTD-1 therefore shows an influence on the coagulation parameters in human blood without additionally influencing the coagulation by bacterial products such as LPS or LTA.
- the present invention therefore relates to the use of theta-defensin from the rhesus monkey for the production of a medicament for the treatment and / or prophylaxis of bacteria and / or sepsis.
- the disease triggers can be gram-positive bacteria, gram-negative bacteria, bacterial products, viruses or yeasts.
- the invention further relates to the use of RTD-1 for the production of a medicament for binding bacterial products such as LPS and / or LTA.
- the invention further relates to the use of RTD-1 for the manufacture of a medicament for the treatment of disease states which are characterized by changes in blood coagulation.
- Table 1 Minimum inhibitory concentrations of RTD-1, vancomycin and ampicillin on various bacterial species determined by the NCCLS method. The table shows the concentration of the respective compounds which showed a clear inhibition of the growth of the bacteria.
- Bacterial suspensions are administered intraperitoneally (i.p.) in CFW-1 mice.
- the mice are obtained from Harlan. After 30 min. the animals are then treated intravenously (IV) with RTD-1 in various doses. The survival of the animals with and without therapy results in the success of the therapy.
- mice survival of mice after ip infection with S. aureus in the bacteremia model and therapy with 0.1, 1 and 10 mg / kg RTD-1 IV.
- the mice are infected with 1.68 x 10 7 colonies of S. aureus ATCC Smith ip and treated iv after 30 min with the indicated doses.
- mice survival of mice after ip infection with S. pneumoniae in the bacteremia model and therapy with 0.1, 1 and 10 mg / kg RTD-1 i. ..
- the mice are infected with 3 ⁇ 10 3 colonies of S. pneumoniae L3TV ip and treated iv after 30 min with the indicated doses.
- mice survival of mice after ip infection with E. coli in the bacteremia model and therapy with 0.1, 1 and 10 mg / kg RTD-1 IV.
- the mice are infected with 1.68 x 10 7 colonies of E. coli Neumann ip and treated iv after 30 min with the indicated doses.
- LPS is injected ip into mice and at different times before and after the LPS administration, RTD-1 is administered iv in various doses to simulate septic shock.
- the survival of the animals is the measure of the therapeutic success in the model for septic shock.
- a relevant affinity of the RTD-1 for binding bacterial products can be calculated from the inhibition.
- Table 6 LPS and LTA binding by RTD-1 and Polymyxin B after 4 hours of incubation. The concentration at which the fluorescence of dansyl polymyxin is reduced by 50% is indicated.
- the membrane permeability of bacteria under the influence of RTD-1 is investigated using a fluorescence method (Silvestro et al. (2000), Antimicrob. Agents Chemotherap. 44, 602-607). This allows an evaluation of the potential of the RTD-1 with regard to damage to the cell membrane of bacteria and thus on the release of bacterial products.
- Table 7 Membrane potential change under the influence of RTD-1 and polymyxin B after 10 minutes exposure to S. aureus bacteria. It shows the concentration that leads to a 50% change in the fluorescence signal.
- Table 7 Membrane potential change under the influence of RTD-1 and polymyxin B.
- RTD-1 becomes a membrane fraction from E. coli (as an example for gram-negative bacteria) or from Bacillus megaterium (as an example for gram-positive bacteria) and the necessary substrates and the inhibitory activity is determined (Chandrakala, B. et al. (2001) Antimicrob. Agents Chemother. 45, 768-775). This approach determines the incorporation of radioactive precursors into high-molecular peptidoglycan via binding to wheat germ agglutinin.
- An influence of RTD-1 on the cell wall synthesis in bacteria provides essential information on an effect on the bacterium (e.g. lysis) and in particular in connection with the release of bacterial products, which is an essential prerequisite for assessing the therapeutic potential of RTD-1 in severe Infections including septic shock.
- Table 8 Inhibition of cell wall synthesis by RTD-1, ampicillin (Sigma), a lactam antibiotic, chloramphenicol (Sigma), a protein biosynthesis inhibitor and vancomycin (Sigma), a glycopeptide antibiotic.
- ampicillin Sigma
- a lactam antibiotic a lactam antibiotic
- chloramphenicol Sigma
- a protein biosynthesis inhibitor a protein biosynthesis inhibitor
- vancomycin Sigma
- glycopeptide antibiotic The inhibition of binding to wheat germ agglutinin from radioactive precursors in high-molecular peptidoglycan is shown. Only substances that influence cell wall biosynthesis, but not protein biosynthesis inhibitors, show inhibition in this approach.
- This parameter is used to determine faults in the exogenous system of
- Blood coagulation used.
- the thromboplastin time is determined in the citrate plasma after adding calcium and tissue factor.
- blood is taken from healthy people of both sexes in collecting vessels with citrate (Monovetten, Sarstedt, Nümbrecht, Germany) and the plasma is obtained after centrifugation. Samples of this plasma are incubated with various concentrations of the test compounds for 10 minutes at 37 ° C. Thereafter, thromplastin (Recombiplastin, OrthoDiagnostic Systems, Neckargemünd, Germany) is added to start the exogenous path of blood clotting. In a device for determining coagulation (coagulometer, Amelung, KC 4A micro), this approach is mixed and the coagulation time is determined.
- This parameter is used to determine disorders in the endogenous blood coagulation system.
- the thromboplastin time is determined in the citrate
- Plasma after adding an activator and phospholipid Plasma after adding an activator and phospholipid.
- blood is taken from healthy people of both sexes in collecting vessels with citrate (Monovetten, Sarstedt, Nürnbrecht, Germany) and the plasma is obtained after centrifugation. Samples of this plasma are incubated with various concentrations of the test compounds for 10 minutes at 37 ° C. Then the activator
- Kaolin and phospholipid (aPTT reagent, Diagnostica Stago, Asnieres, France) added.
- the coagulation is started by adding 0.025 M calcium chloride to this mixture.
- a device for determining coagulation coagulometer, Amelung, KC 4A micro
- this approach is mixed and the coagulation time is determined.
- Table 10 Influencing of the coagulation parameters aPTT, PT, and the clotting time of whole human blood under the influence of RTD-1. Measured clotting time is shown in seconds after adding RTD-1.
- Table 10 Influencing of the coagulation parameters aPTT, PT, and the clotting time of whole human blood under the influence of RTD-1.
- Plasma samples are obtained by bleeding the animals at various times after LPS or SEB administration in mice. Plasma samples are taken from these blood samples and subjected to a cytokine analysis. The amount of cytokine in the
- Plasma is determined quantitatively using the CBA methods (CBA system, BectonDickinson, Heidelberg, Germany).
- Table 11 Cytokine modulation after therapy with RTD-1 in the mouse model of septic shock after administration of LPS. The maximum percentage change compared to the untreated LPS control is given. negative Values indicate a decrease, positive values indicate an increase in the amount of cytokine in the plasma.
- Table 11 Cytokine modulation after therapy with RTD-1 in the mouse model of septic shock after administration of LPS.
- Table 12 Cytokine modulation after therapy with RTD-1 in the mouse model of septic shock after administration of SEB. The maximum percentage change compared to the untreated SEB control is given. negative
- Values indicate a decrease, positive values indicate an increase in the amount of cytokine in the plasma.
- Blood is drawn from healthy donors and infected with bacteria in vitro. Both gram-positive pathogens (S. aureus) and gram-negative pathogens (E. coli) are used. After the pathogens have been added, samples of the infected and infected and treated blood are taken at defined times and the plasma is obtained by centrifugation. The amount of cytokine in the plasma is determined quantitatively using the CBA methods (CBA system, BectonDickinson, Heidelberg, Germany). In addition, the analysis for MIF is carried out by ELISA technology (human MIF ELISA system, R&D Systems Inc., Minneapolis, USA).
- Table 13 Cytokine modulation after therapy with RTD-1 in the infection model with whole human blood after administration of S. aureus. The maximum percentage change in pro-inflammatory mediators compared to the untreated infection control is given. Negative values indicate a decrease, positive values indicate an increase in the amount of cytokine in the blood culture.
- Table 13 Cytokine modulation after therapy with RTD-1 in the infection model with whole human blood after administration of S. aureus.
- Table 14 Cytokine modulation after therapy with RTD-1 in the infection model with whole human blood after administration of E. coli The maximum percentage change compared to the untreated infection control is given. Negative values indicate a decrease, positive values indicate an increase in the amount of cytokine in the blood culture.
- RTD-1 can be converted in a known manner into the customary formulations, such as tablets, dragées, pills, granules, aerosols, syrups, emulsions, suspensions and solutions, using inert, non-toxic, pharmaceutically suitable excipients or solvents.
- the therapeutically active compound should in each case be present in a concentration of 0.5 to 90% by weight of the total mixture, i.e. in amounts sufficient to achieve the dosage range indicated.
- the formulations are prepared, for example, by stretching the active ingredients with solvents and / or carriers, if appropriate using emulsifiers and / or dispersants, it being possible, for example if organic solvents to be used as diluents, to use organic solvents as auxiliary solvents.
- the application is carried out in the usual way, preferably intravenously, transdermally, orally or parenterally, in particular orally or intravenously. However, it can also be done by inhalation via the mouth or nose, for example with the aid of a spray, or topically via the skin.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Marine Sciences & Fisheries (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03735502A EP1523324A1 (de) | 2002-06-13 | 2003-05-30 | Behandlung von schweren infektionen und septischem schock |
AU2003238175A AU2003238175A1 (en) | 2002-06-13 | 2003-05-30 | Treatment of serious infections and septic shock |
CA002489244A CA2489244A1 (en) | 2002-06-13 | 2003-05-30 | Treatment of serious infections and septic shock |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10226216.0 | 2002-06-13 | ||
DE10226216A DE10226216A1 (de) | 2002-06-13 | 2002-06-13 | Behandlung von schweren Infektionen und septischem Schock |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003105883A1 true WO2003105883A1 (de) | 2003-12-24 |
Family
ID=29594458
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2003/005694 WO2003105883A1 (de) | 2002-06-13 | 2003-05-30 | Behandlung von schweren infektionen und septischem schock |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1523324A1 (de) |
AU (1) | AU2003238175A1 (de) |
CA (1) | CA2489244A1 (de) |
DE (1) | DE10226216A1 (de) |
WO (1) | WO2003105883A1 (de) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006084463A1 (en) * | 2005-02-08 | 2006-08-17 | Novozymes A/S | Systemic treatment of infections with defensins |
US7119070B2 (en) | 2002-04-30 | 2006-10-10 | The Regents Of The University Of California | Antimicrobial theta defensins, analogs thereof, and methods of use |
WO2012167077A1 (en) * | 2011-06-02 | 2012-12-06 | The Regents Of The University Of California | Blockade of inflammatory proteases with theta - defensins |
WO2020264328A1 (en) * | 2019-06-26 | 2020-12-30 | Selsted Michael E | Compositions and methods for treatment of fungal infections |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20170035845A1 (en) * | 2015-08-07 | 2017-02-09 | The Regents Of The University Of California | Compositions and Methods for Inhibiting Pro-Inflammatory Cytokine Gene Expression |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000068265A1 (en) * | 1999-05-10 | 2000-11-16 | The Regents Of The University Of California | Antimicrobial theta defensins and methods of using same |
-
2002
- 2002-06-13 DE DE10226216A patent/DE10226216A1/de not_active Withdrawn
-
2003
- 2003-05-30 EP EP03735502A patent/EP1523324A1/de not_active Withdrawn
- 2003-05-30 CA CA002489244A patent/CA2489244A1/en not_active Abandoned
- 2003-05-30 WO PCT/EP2003/005694 patent/WO2003105883A1/de not_active Application Discontinuation
- 2003-05-30 AU AU2003238175A patent/AU2003238175A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000068265A1 (en) * | 1999-05-10 | 2000-11-16 | The Regents Of The University Of California | Antimicrobial theta defensins and methods of using same |
Non-Patent Citations (2)
Title |
---|
S.A. MUHLE ET AL.: "Design of gram-negative selective antimicrobial peptides.", BIOCHEMISTRY., vol. 40, no. 19, 2001, EASTON, PA, US, pages 5777 - 5785, XP002256643 * |
Y.-Q. TANG ET AL.: "A CYCLIC ANTIMICROBIAL PEPTIDE PRODUCED IN PRIMATE LEUKOCYTES BY THE LIGATION OF TWO TRUNCATED ALPHA-DEFENSINS", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 286, no. 5439, 1999, pages 498 - 502, XP000919300, ISSN: 0036-8075 * |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7119070B2 (en) | 2002-04-30 | 2006-10-10 | The Regents Of The University Of California | Antimicrobial theta defensins, analogs thereof, and methods of use |
US7462598B2 (en) | 2002-04-30 | 2008-12-09 | The Regents Of The University Of California | Antimicrobial theta defensins, analogs thereof, and methods of use |
WO2006084463A1 (en) * | 2005-02-08 | 2006-08-17 | Novozymes A/S | Systemic treatment of infections with defensins |
JP2019014722A (ja) * | 2011-06-02 | 2019-01-31 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアThe Regents Of The University Of California | シータデフェンシンによる炎症性プロテアーゼの遮断 |
KR102060207B1 (ko) * | 2011-06-02 | 2019-12-30 | 더 리전츠 오브 더 유니버시티 오브 캘리포니아 | 세타-디펜신들로 염증성 프로테아제들의 차단 |
US9346866B2 (en) | 2011-06-02 | 2016-05-24 | The Regents Of The University Of California | Inhibition of tace activity with cyclic peptides |
JP2017149745A (ja) * | 2011-06-02 | 2017-08-31 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアThe Regents Of The University Of California | シータデフェンシンによる炎症性プロテアーゼの遮断 |
RU2652605C2 (ru) * | 2011-06-02 | 2018-04-27 | Зе Реджентс Оф Зе Юниверсити Оф Калифорния | Блокада воспалительных протеаз тета-дефензинами |
WO2012167077A1 (en) * | 2011-06-02 | 2012-12-06 | The Regents Of The University Of California | Blockade of inflammatory proteases with theta - defensins |
US10512669B2 (en) | 2011-06-02 | 2019-12-24 | The Regents Of The University Of California | Blockade of inflammatory proteases with cyclic peptides |
JP2014516990A (ja) * | 2011-06-02 | 2014-07-17 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | シータデフェンシンによる炎症性プロテアーゼの遮断 |
US10603356B2 (en) | 2011-06-02 | 2020-03-31 | The Regents Of The University Of California | Compositions and method for treatment of inflammatory bowel disease |
KR102456795B1 (ko) * | 2011-06-02 | 2022-10-19 | 더 리전츠 오브 더 유니버시티 오브 캘리포니아 | 세타-디펜신들로 염증성 프로테아제들의 차단 |
KR20210075218A (ko) * | 2011-06-02 | 2021-06-22 | 더 리전츠 오브 더 유니버시티 오브 캘리포니아 | 세타-디펜신들로 염증성 프로테아제들의 차단 |
US11021518B2 (en) | 2019-06-26 | 2021-06-01 | The University Of Southern California | Theta defensin analogs |
US11427617B2 (en) | 2019-06-26 | 2022-08-30 | The University Of Southern California | Compositions and methods for treatment of fungal infections |
WO2020264328A1 (en) * | 2019-06-26 | 2020-12-30 | Selsted Michael E | Compositions and methods for treatment of fungal infections |
Also Published As
Publication number | Publication date |
---|---|
CA2489244A1 (en) | 2003-12-24 |
EP1523324A1 (de) | 2005-04-20 |
AU2003238175A1 (en) | 2003-12-31 |
DE10226216A1 (de) | 2003-12-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CH640140A5 (de) | Verfahren zur herstellung von intravenoes injizierbarem gamma-globulin. | |
DE2832204A1 (de) | Mittel zur behandlung von nervenerkrankungen, verfahren zu seiner herstellung und seine verwendung | |
DE69726457T2 (de) | Pharmazeutische zusammensetzungen mit antimikrobieller wirkung | |
DE3026180C2 (de) | Rifamycin-SV-Salze von basischen Aminosäuren, Verfahren zu ihrer Herstellung und Arzneimittel zur intraartikulären Injektion bei der Bekämpfung von rheumatoider Arthritis | |
DE19505287A1 (de) | Zusammensetzung und Verfahren zur Prävention und Behandlung von Entzündungen mit Immunglobulin A | |
DE102005053926B3 (de) | Verwendung eines antibakteriellen Mittels aus einer Mischung aus Pflanzendrogen oder Extrakten daraus | |
DE69333258T2 (de) | Verwendung von lysozymdimer zur herstellung eines arzneimittels zur modulation der natürlichen abwehrvorgänge | |
WO2003105883A1 (de) | Behandlung von schweren infektionen und septischem schock | |
DE69824358T2 (de) | Peptidfragment von LALF mit antiviraler Wirkung | |
DE60130906T2 (de) | Synergistische wirkungen von hgf und antibakterieller behandlung | |
EP0864579A2 (de) | Wismutsalze von Antibiotika der Moenomycin-Gruppe, Verfahren zu ihrer Herstellung, ihre Verwendung und solche Salze enthaltende Arzneimittel | |
DE2751454A1 (de) | Steuerung und umkehr der immunologischen alterung | |
DE69929616T2 (de) | Oxyhuminsäure und ihre verwendung zur behandlung von verschiedenenen störungen | |
DE69914957T2 (de) | Nicht-festes topisch anzuwendendes arzneimittel enthaltend glyzerol und alchemilla vulgaris extrakt | |
EP0482133B1 (de) | Verwendung von lactoferrin zur bekämpfung der toxischen wirkung des endotoxins | |
WO2003028746A1 (de) | Verfahren zur herstellung von extrakten aus pelargonium sidoides und/oder pelargonium reniforme und deren verwendung | |
DE2546001C3 (de) | Immunostimulierende, Phospholipide enthaltende Stoffgemische, diese Stoffgemische enthaltende Arzneimittel und Verfahren zu ihrer Gewinnung | |
EP2077117A1 (de) | Mittel mit immunregulatorischer wirkung und seine anwendung zur behandlung von autoimmunkrankheiten | |
CH657989A5 (de) | Biologisch aktive substanz, verfahren zur herstellung der substanz, sowie die substanz enthaltende, immunoaktive zusammensetzung. | |
EP0348507A1 (de) | Arzneimittelzubereitung für die individuelle prophylaxe venerischer krankheiten und zur heilung von urogenitaler trichomoniase | |
EP1480646B1 (de) | Antiinfektiva und/oder immunmodulatoren zur präventiven therapie nach akutem schlaganfall | |
WO2021259423A1 (de) | Verwendung von co-enzym-antagonisten zur stoffwechselverlangsamung | |
EP0561145A1 (de) | Verwendung einer chemisch stabilisierten Chloritmatrix zur Herstellung von Arzneimitteln zur Behandlung von HIV-Infektionen | |
WO1999061045A1 (de) | Topisch anwendbares arzneimittel zur behandlung von virusinfektionen | |
CH640865A5 (de) | Glykoproteid des menschlichen urins, verfahren zu seiner herstellung und mittel zur bekaempfung von leukozytopenie. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2003735502 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2489244 Country of ref document: CA |
|
WWP | Wipo information: published in national office |
Ref document number: 2003735502 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2003735502 Country of ref document: EP |